{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=6+cycles+of+standard+chemotherapy", "query": { "intervention": "6 cycles of standard chemotherapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 448, "total_pages": 45, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=6+cycles+of+standard+chemotherapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T11:39:39.242Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06782932", "title": "Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "AGEN2373", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GVAX", "type": "DRUG" }, { "name": "AGEN2373 (RP2D)", "type": "DRUG" }, { "name": "mKRASvax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2025-05-27", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-09-29T11:39:39.242Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06782932" }, { "nct_id": "NCT03128008", "title": "Locally Advanced NSCLC Hyperfractionated RT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non Small Cell Lung (NSCLC)" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Daily hyperfractionated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-12-07", "completion_date": "2021-01-27", "has_results": true, "last_update_posted_date": "2021-05-28", "last_synced_at": "2026-09-29T11:39:39.242Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03128008" }, { "nct_id": "NCT00715793", "title": "Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hussein Tawbi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2008-06", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-10-03", "last_synced_at": "2026-09-29T11:39:39.242Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00715793" }, { "nct_id": "NCT02228772", "title": "Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma", "B-cell Adult Acute Lymphoblastic Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "MLN 9708", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "51 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "51 Years to 75 Years" }, "enrollment_count": 19, "start_date": "2014-12", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2019-11-26", "last_synced_at": "2026-09-29T11:39:39.242Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02228772" }, { "nct_id": "NCT01038752", "title": "Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Suramin Drug:Docetaxel Drug: Carboplatin", "type": "DRUG" }, { "name": "Placebo Drug: Docetaxel Drug: Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Optimum Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2010-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-05-21", "last_synced_at": "2026-09-29T11:39:39.242Z", "location_count": 2, "location_summary": "Chicago, Illinois • Richmond, Virginia", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01038752" }, { "nct_id": "NCT04682158", "title": "Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "3 Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Propranolol", "type": "DRUG" }, { "name": "Intensity Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2021-04-01", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-09-29T11:39:39.242Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04682158" }, { "nct_id": "NCT02420314", "title": "Pharmacological Ascorbate for Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ascorbic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joseph J. Cullen, MD, FACS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2015-04", "completion_date": "2022-08-27", "has_results": true, "last_update_posted_date": "2024-08-20", "last_synced_at": "2026-09-29T11:39:39.242Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420314" }, { "nct_id": "NCT04197687", "title": "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Adenocarcinoma", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Multi-epitope HER2 Peptide Vaccine TPIV100", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 480, "start_date": "2020-02-20", "completion_date": "2025-01-15", "has_results": false, "last_update_posted_date": "2023-12-18", "last_synced_at": "2026-09-29T11:39:39.242Z", "location_count": 30, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04197687" }, { "nct_id": "NCT02275533", "title": "Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Clinical Observation", "type": "OTHER" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2015-07-02", "completion_date": "2026-10-08", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-09-29T11:39:39.242Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02275533" }, { "nct_id": "NCT04900792", "title": "A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Ferumoxytol injection", "type": "DRUG" }, { "name": "Pharmacological ascorbate", "type": "DRUG" }, { "name": "External beam radiation therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Bryan Allen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2023-02-28", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-29T11:39:39.242Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900792" } ] }